Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
138 Leser
Artikel bewerten:
(0)

Equashield to Host Symposium Featuring World's First Drug Compounding Robot with Closed System Transfer Device

PORT WASHINGTON, New York, April 3, 2018 /PRNewswire/ --

Satellite Symposium at ISOPP 2018 Focusing on Robotics in Cytotoxics to Feature Leading Experts an Augmented Reality Tour of Equashield Pro Hazardous Drug Compounding Robot

Equashield (equashield.com), a leadingproviderofClosed System TransferDevices(CSTDs) for hazardous drugs, announced today that it will be leading a symposium exploring the use of robotics in cytotoxic drug handling at the International Symposium on Oncology Pharmacy Practice (ISOPP).

The symposium will introduce the Equashield Pro, the first drug compounding robot utilizing Equashield's proprietary CSTD technology. It will also discuss the role that the Equashield Pro will play in increasing pharmacy throughput while simultaneously keeping pharmacists safe.

The symposium will feature presentations from leading industry experts:

  • Yaakov Cass, District Pharmacist Emeritus for the Israeli Ministry of Health, on Robotics in Cytotoxics: The Final Frontier.
  • Dr. Salim Hadad, Director of the Pharmaceutical Services Department at Rambam Medical Center, on What Role Can Equashield Robots Play in Keeping Pharmacists Safe.

Equashield's symposium will also include an augmented reality demonstration of the Equashield Pro robot.

"The Equashield Pro provides the solution to hazardous drug compounding problems encountered by practicing hospital pharmacists on a daily basis," said Marino Kriheli, Co-Founder of Equashield. "By combining leading robotic automation with Equashield's proprietary CSTD technology, the Equashield Pro significantly speeds up the process of compounding hazardous drugs and creates a safer environment for oncology pharmacists around the world."

Utilizing advanced robotic technologies, the Equashield Pro enables quick compounding of a large variety of patient specific chemotherapy doses using a method that shortens the process flow while performing multiple simultaneous tasks. Comparable in size to a standard Biological Safety Cabinet, it is easily integrated into hospital pharmacies, while dose verification software protects against cases of medication dosage and identification errors.

ISOPP 2018 will be held in Shanghai, China, at the Kerry Hotel Pudong - April 11 - 13, 2018. The Equashield symposium will take place from 12:30 - 14:00 on Wednesday, April 11. To set up a meeting with an Equashield representative, please contact info@equashield.com or visit https://www.equashield.com/.

About Equashield

Equashield isa leading provider of a full range of manual and automated solutions to hospitals for the compounding and administration of hazardous drugs. Equashield's product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELDPro, the first ever closed system drug compounding robot. Equashield's CSTD is clinically-proven to protect healthcare professionals from hazardous drug exposure. The globally awarded EQUASHIELD II covers more routes of exposure than alternative systems by preventing contaminationof syringe plungers and drug residuals on connector surfaces, as well as exposure to drug vapors. Studies have shown Equashield's CSTD to be faster to deploy and easier to use than competing systems, and the system has passed the proposed 2015 alcohol vapor containment protocol from NIOSH, confirming that it can contain the harshest vapors & emissions. EQUASHIELD is in use by hundreds of hospitals and clinics around the world, and has been both cleared by the FDA under the ONB product code, and substantiated in FDA-cleared labeling as preventing microbial ingress for up to seven days.

For more information: http://www.equashield.com

Follow Equashield on LinkedIn, Twitter and Facebook.

Media Contact:
Finn Partners for Equashield
Nicole Grubner
nicole.grubner@finnpartners.com
@nicolegrubner
+1-929-222-8011


Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.